BACKGROUND: Both the prevalence and extent of brain magnetic resonance imaging (MRI) abnormalities are related to risk factors for dementia. Typically these associations have been explored separately, but an integrated modeling approach would allow the separate relationships to be consistently described and contrasted. METHODS: Region-specific measures of ischemic lesion volumes were obtained from standardized brain MRI from 1,403 women enrolled in the Women's Health Initiative hormone therapy trials. Mixed-effects mixed-distribution models were fitted to explore jointly the relationships that the region-specific prevalence of ischemic lesions and region-specific ischemic lesion volumes had with risk factors and scores from tests of cognitive function. RESULTS: Women with greater probabilities (prevalence) of having ischemic lesions in brain regions also tended to have larger volumes (extent) of ischemic lesions within the affected regions (p < 0.001). Across the 5 regions included in analyses (frontal, limbic, occipital, parietal and temporal), prevalence and extent varied (p < 0.001). Each was increased among women who were older, had hypertension or who had previously been classified as cognitively impaired (p < 0.01). Additionally, extent was significantly increased among women with a history of smoking (p = 0.02). Cognitive function tests were more strongly related to the extent than prevalence of ischemic lesions and relationships varied among cognitive domains (p < 0.001). CONCLUSIONS: Mixed-effects mixed-distribution models provide a coherent basis for examining relationships involving the prevalence and extent of ischemic brain lesions. Across the cohort and regions we examined, relationships with risk factors and cognitive function appeared to be stronger for extent than for prevalence. 2009 S. Karger AG, Basel.
BACKGROUND: Both the prevalence and extent of brain magnetic resonance imaging (MRI) abnormalities are related to risk factors for dementia. Typically these associations have been explored separately, but an integrated modeling approach would allow the separate relationships to be consistently described and contrasted. METHODS: Region-specific measures of ischemic lesion volumes were obtained from standardized brain MRI from 1,403 women enrolled in the Women's Health Initiative hormone therapy trials. Mixed-effects mixed-distribution models were fitted to explore jointly the relationships that the region-specific prevalence of ischemic lesions and region-specific ischemic lesion volumes had with risk factors and scores from tests of cognitive function. RESULTS:Women with greater probabilities (prevalence) of having ischemic lesions in brain regions also tended to have larger volumes (extent) of ischemic lesions within the affected regions (p < 0.001). Across the 5 regions included in analyses (frontal, limbic, occipital, parietal and temporal), prevalence and extent varied (p < 0.001). Each was increased among women who were older, had hypertension or who had previously been classified as cognitively impaired (p < 0.01). Additionally, extent was significantly increased among women with a history of smoking (p = 0.02). Cognitive function tests were more strongly related to the extent than prevalence of ischemic lesions and relationships varied among cognitive domains (p < 0.001). CONCLUSIONS: Mixed-effects mixed-distribution models provide a coherent basis for examining relationships involving the prevalence and extent of ischemic brain lesions. Across the cohort and regions we examined, relationships with risk factors and cognitive function appeared to be stronger for extent than for prevalence. 2009 S. Karger AG, Basel.
Authors: Charles DeCarli; Joseph Massaro; Danielle Harvey; John Hald; Mats Tullberg; Rhoda Au; Alexa Beiser; Ralph D'Agostino; Philip A Wolf Journal: Neurobiol Aging Date: 2005-04 Impact factor: 4.673
Authors: Susan M Resnick; Laura H Coker; Pauline M Maki; Stephen R Rapp; Mark A Espeland; Sally A Shumaker Journal: Clin Trials Date: 2004 Impact factor: 2.486
Authors: R N Bryan; J Cai; G Burke; R G Hutchinson; D Liao; J F Toole; A P Dagher; L Cooper Journal: AJNR Am J Neuroradiol Date: 1999-08 Impact factor: 3.825
Authors: Robertus H C Bisschops; Catharina J M Klijn; L Jaap Kappelle; Alexander C van Huffelen; Jeroen van der Grond Journal: Arch Neurol Date: 2003-09
Authors: R Schmidt; Ph Scheltens; T Erkinjuntti; L Pantoni; H S Markus; A Wallin; F Barkhof; F Fazekas Journal: Neurology Date: 2004-07-13 Impact factor: 9.910
Authors: S A Shumaker; B A Reboussin; M A Espeland; S R Rapp; W L McBee; M Dailey; D Bowen; T Terrell; B N Jones Journal: Control Clin Trials Date: 1998-12
Authors: M Haan; M A Espeland; B E Klein; R Casanova; S A Gaussoin; R D Jackson; A E Millen; S M Resnick; J E Rossouw; S A Shumaker; R Wallace; K Yaffe Journal: Neurology Date: 2012-03-14 Impact factor: 9.910
Authors: Laura H Coker; Mark A Espeland; Patricia E Hogan; Susan M Resnick; R Nick Bryan; Jennifer G Robinson; Joseph S Goveas; Christos Davatzikos; Lewis H Kuller; Jeff D Williamson; Cheryl D Bushnell; Sally A Shumaker Journal: Neurology Date: 2014-01-02 Impact factor: 9.910
Authors: Bernhard Haring; Xiaoyan Leng; Jennifer Robinson; Karen C Johnson; Rebecca D Jackson; Rebecca Beyth; Jean Wactawski-Wende; Moritz Wyler von Ballmoos; Joseph S Goveas; Lewis H Kuller; Sylvia Wassertheil-Smoller Journal: J Am Heart Assoc Date: 2013-12-18 Impact factor: 5.501